1. Home
  2. TCBX vs CBIO Comparison

TCBX vs CBIO Comparison

Compare TCBX & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Third Coast Bancshares Inc.

TCBX

Third Coast Bancshares Inc.

HOLD

Current Price

$38.31

Market Cap

628.8M

Sector

Finance

ML Signal

HOLD

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$16.92

Market Cap

557.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
TCBX
CBIO
Founded
2008
2003
Country
United States
United States
Employees
N/A
44
Industry
Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
628.8M
557.8M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
TCBX
CBIO
Price
$38.31
$16.92
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$45.00
$26.67
AVG Volume (30 Days)
61.6K
276.8K
Earning Date
04-22-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
36.33
N/A
EPS
0.88
N/A
Revenue
N/A
N/A
Revenue This Year
$29.99
N/A
Revenue Next Year
$10.14
$279.20
P/E Ratio
$43.15
N/A
Revenue Growth
N/A
N/A
52 Week Low
$29.68
$8.72
52 Week High
$43.84
$27.41

Technical Indicators

Market Signals
Indicator
TCBX
CBIO
Relative Strength Index (RSI) 51.70 38.78
Support Level $36.39 $10.83
Resistance Level $38.86 $21.14
Average True Range (ATR) 0.78 2.20
MACD 0.16 -0.23
Stochastic Oscillator 62.21 4.17

Price Performance

Historical Comparison
TCBX
CBIO

About TCBX Third Coast Bancshares Inc.

Third Coast Bancshares Inc is a bank holding company. It focuses on providing commercial banking solutions to small and medium-sized businesses and professionals with operations in its markets. The bank operates twenty branches in the Greater Houston, Dallas-Fort Worth, and Austin-San Antonio markets, one branch in Ballinger, Texas, and one branch in Detroit, Texas. The company operates through one segment, community banking, It generates the majority of its revenue from interest on loans, customer service, and loan fees.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: